Since inhibition of osteoclast activity was seen in the patients treated with ED71 but not with 1,25(OH)2D3, this work confirms that HIF1α could be a target to treat postmenopausal osteoporosis patients. The gene discussed is HIF1A; the disease is postmenopausal osteoporosis.